Literature DB >> 21776329

Autoimmune mechanisms of scleroderma and a role of oxidative stress.

Toshiyuki Yamamoto1.   

Abstract

Scleroderma is a fibrotic condition characterized by immunological abnormalities, vascular injury and increased accumulation of extracellular matrix proteins in the skin. Although the etiology of scleroderma has not yet been fully elucidated, a growing body of evidence suggests that extracellular matrix overproduction by activated fibroblasts results from complex interactions among endothelial cells, lymphocytes, macrophages and fibroblasts via a number of mediators, such as cytokines, chemokines and growth factors. Recent investigations have further suggested that reactive oxygen species (ROS) are involved and play a role of autoimmunology in scleroderma. In this review, current findings on the autoimmune mechanisms in the pathophysiology of scleroderma are described.

Entities:  

Year:  2011        PMID: 21776329      PMCID: PMC3136898          DOI: 10.4161/self.2.1.14058

Source DB:  PubMed          Journal:  Self Nonself        ISSN: 1938-2030


  97 in total

1.  Defective vasculogenesis in systemic sclerosis.

Authors:  Masataka Kuwana; Yuka Okazaki; Hidekata Yasuoka; Yutaka Kawakami; Yasuo Ikeda
Journal:  Lancet       Date:  2004 Aug 14-20       Impact factor: 79.321

2.  Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease?

Authors:  Maki Murata; Manabu Fujimoto; Takashi Matsushita; Yasuhito Hamaguchi; Minoru Hasegawa; Kazuhiko Takehara; Kazuhiro Komura; Shinichi Sato
Journal:  J Dermatol Sci       Date:  2008-03-07       Impact factor: 4.563

3.  Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin-3-gallate.

Authors:  Audrey Dooley; Xu Shi-Wen; Nima Aden; Thomas Tranah; Nirupa Desai; Christopher P Denton; David J Abraham; Richard Bruckdorfer
Journal:  Rheumatology (Oxford)       Date:  2010-07-13       Impact factor: 7.580

4.  Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis.

Authors:  O Distler; T Pap; O Kowal-Bielecka; R Meyringer; S Guiducci; M Landthaler; J Schölmerich; B A Michel; R E Gay; M Matucci-Cerinic; S Gay; U Müller-Ladner
Journal:  Arthritis Rheum       Date:  2001-11

5.  Expression of multiple chemokine genes by a human mast cell leukemia.

Authors:  R S Selvan; J H Butterfield; M S Krangel
Journal:  J Biol Chem       Date:  1994-05-13       Impact factor: 5.157

6.  Increased serum levels of N(epsilon)-(hexanoyl)lysine, a new marker of oxidative stress, in systemic sclerosis.

Authors:  Kazuhiro Shimizu; Fumihide Ogawa; Yuichiro Akiyama; Eiji Muroi; Ayumi Yoshizaki; Yohei Iwata; Kazuhiro Komura; Sangjae Bae; Shinichi Sato
Journal:  J Rheumatol       Date:  2008-09-01       Impact factor: 4.666

7.  Monocytes of patients wiht systemic sclerosis (scleroderma spontaneously release in vitro increased amounts of superoxide anion.

Authors:  P Sambo; L Jannino; M Candela; A Salvi; M Donini; S Dusi; M M Luchetti; A Gabrielli
Journal:  J Invest Dermatol       Date:  1999-01       Impact factor: 8.551

8.  Expression of platelet-derived growth factor B-chain and platelet-derived growth factor beta-receptor in fibroblasts of scleroderma.

Authors:  X Y Zheng; J Z Zhang; P Tu; S Q Ma
Journal:  J Dermatol Sci       Date:  1998-11       Impact factor: 4.563

Review 9.  Circulating fibrocytes: collagen-secreting cells of the peripheral blood.

Authors:  Timothy E Quan; Shawn Cowper; Sou-Pan Wu; Linda K Bockenstedt; Richard Bucala
Journal:  Int J Biochem Cell Biol       Date:  2004-04       Impact factor: 5.085

10.  Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea.

Authors:  E Antiga; P Quaglino; S Bellandi; W Volpi; E Del Bianco; A Comessatti; S Osella-Abate; C De Simone; A Marzano; M G Bernengo; P Fabbri; M Caproni
Journal:  Br J Dermatol       Date:  2010-01-22       Impact factor: 9.302

View more
  11 in total

Review 1.  Fibrosis--a lethal component of systemic sclerosis.

Authors:  Yuen Yee Ho; David Lagares; Andrew M Tager; Mohit Kapoor
Journal:  Nat Rev Rheumatol       Date:  2014-04-22       Impact factor: 20.543

Review 2.  NADPH oxidase enzymes in skin fibrosis: molecular targets and therapeutic agents.

Authors:  Olubukola Babalola; Andrew Mamalis; Hadar Lev-Tov; Jared Jagdeo
Journal:  Arch Dermatol Res       Date:  2013-10-24       Impact factor: 3.017

Review 3.  Innate Immunity in Systemic Sclerosis.

Authors:  Christopher Dowson; Nathan Simpson; Laura Duffy; Steven O'Reilly
Journal:  Curr Rheumatol Rep       Date:  2017-01       Impact factor: 4.592

4.  The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the in vivo Treatment of Immune-Related Diseases: A Systematic Review.

Authors:  Alessander Leyendecker; Carla Cristina Gomes Pinheiro; Mariane Tami Amano; Daniela Franco Bueno
Journal:  Front Immunol       Date:  2018-09-11       Impact factor: 7.561

5.  Serum prolidase enzyme activity and oxidative status in patients with fibromyalgia.

Authors:  Mehtap Bozkurt; Mehmet Caglayan; Pelin Oktayoglu; Serda Em; Ibrahim Batmaz; Mustafa Akif Sariyildiz; Kemal Nas; Demet Ucar; Hatice Yüksel; Aysegul Jale Sarac
Journal:  Redox Rep       Date:  2014-01-03       Impact factor: 4.412

Review 6.  The role of T helper (TH)17 cells as a double-edged sword in the interplay of infection and autoimmunity with a focus on xenobiotic-induced immunomodulation.

Authors:  Nasr Y A Hemdan; Ahmed M Abu El-Saad; Ulrich Sack
Journal:  Clin Dev Immunol       Date:  2013-09-12

7.  Plasma Glycosaminoglycan Profiles in Systemic Sclerosis: Associations with MMP-3, MMP-10, TIMP-1, TIMP-2, and TGF-Beta.

Authors:  Kornelia Kuźnik-Trocha; Katarzyna Winsz-Szczotka; Katarzyna Komosińska-Vassev; Agnieszka Jura-Półtorak; Anna Kotulska-Kucharz; Eugeniusz J Kucharz; Przemysław Kotyla; Krystyna Olczyk
Journal:  Biomed Res Int       Date:  2020-04-21       Impact factor: 3.411

8.  Metformin ameliorates scleroderma via inhibiting Th17 cells and reducing mTOR-STAT3 signaling in skin fibroblasts.

Authors:  Jeonghyeon Moon; Seon-Yeong Lee; Jeong Won Choi; A Ram Lee; Jin Hee Yoo; Su-Jin Moon; Sung-Hwan Park; Mi-La Cho
Journal:  J Transl Med       Date:  2021-05-04       Impact factor: 5.531

9.  Potential biomarkers and therapeutic targets of idiopathic pulmonary arterial hypertension.

Authors:  Wenjun He; Xi Su; Lingdan Chen; Chunli Liu; Wenju Lu; Tao Wang; Jian Wang
Journal:  Physiol Rep       Date:  2022-01

10.  Association of immunological cell profiles with specific clinical phenotypes of scleroderma disease.

Authors:  José Manuel López-Cacho; Soledad Gallardo; Manuel Posada; Miriam Aguerri; David Calzada; Teodoro Mayayo; María Luisa González-Rodríguez; Antonio María Rabasco; Carlos Lahoz; Blanca Cárdaba
Journal:  Biomed Res Int       Date:  2014-04-10       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.